XOMA Corporation (Nasdaq" XOMA) $3.13. Announced Wednesday after market close its operational highlights and financial results for the quarter ended March 31, 2013.
XOMA reported total revenues of $9.5 million in the first quarter of 2013, compared with $9.9 million in the corresponding period of 2012. The small decrease in 2013 revenues was due primarily to a reduction in contract and other revenue associated with NIAID contracts. For the quarter ended March 31, 2013, XOMA had a net loss of $24.9 million (or $0.30 per share), compared with a net loss of $30.4 million, or $0.69 per share, for the quarter ended March 31, 2012. The net loss for the first quarters of 2013 and 2012 included a non-cash charge of $12.8 million (or $0.16 per share) and $14.4 million (or $0.33 per share), respectively, both of which were related to the revaluation of contingent warrant liabilities, which resulted primarily from the appreciation of XOMA's stock price. Excluding these non-cash charges, net loss in the first quarters of 2013 and 2012 was $12.0 million (or $0.15 per share) and $16.0 million (or $0.36 per share), respectively.
On March 31, 2013, XOMA had cash, cash equivalents, and short-term investments of $70.4 million. The Company ended December 31, 2012, with cash, cash equivalents, and short-term investments of $85.3 million.
What They Do: XOMA combines a portfolio of innovative therapeutic antibodies, both in late-stage clinical development and in preclinical research, with its recently launched commercial operations.
NPS Pharmaceuticals (Nasdaq: NPSP) $13.53. Today announced its results for the first quarter ended March 31, 2013.
NPS reported a net loss of $7.8 million or $0.09 per diluted share for the first quarter of 2013 compared to a net loss of $10.6 million or $0.12 per diluted share for the first quarter of 2012.
Revenues are comprised of net product sales for Gattex and royalty revenues. Sales of Gattex were $654 thousand for the first quarter of 2013, versus $0 for the first quarter of 2012.
What They Do: NPS Pharmaceuticals is a biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide.
Aeroflex Holding Corp. (NYSE: ARX) $7.72. Today announced its financial results for the third quarter of fiscal 2013, which ended March 31, 2013.
Net sales were $161.0 million compared to $162.3 million in the third quarter of fiscal 2012. Operating loss was $(2.5) million and net loss was $(9.4) million, or $(0.11) per share, compared to operating loss of $(61.1) million and a net loss of $(65.3) million, or $(0.77) per share in the third quarter of fiscal 2012. This quarter, operating and net loss included a one-time $8 million International Traffic in Arms Regulation (“ITAR”) settlement expense to resolve historical self-disclosed ITAR violations. The third quarter of fiscal 2012 included a non-cash goodwill and intangibles impairment charge of $59.7 million in the RFMW group.On a Non-GAAP basis, compared to the third quarter of fiscal 2012, operating income was $24.1 million compared to $23.0 million, net income was $9.9 million, or $0.12 per share compared to net income of $7.4 million, or $0.09 per share, and Adjusted EBITDA was $29.4 million compared to Adjusted EBITDA of $27.8 million in the third quarter of fiscal 2012.
What They Do: Aeroflex Holding Corp. is a leading global provider of high performance microelectronic components, and test and measurement equipment used by companies in the space, avionics, defense, commercial wireless communications, medical and other markets.
About SmallCapReview
Copyright SmallCapReview. SmallCapReview.com has been a leading site for information on Small Cap Stocks, Penny Stocks and Microcaps since 1999. Visit http://SmallCapReview.com to sign up for our FREE newsletter.